Researchers evaluated the effectiveness of restriction spectrum imaging (RSI-MRI) as a biomarker for predicting upgrading in prostate cancer patients undergoing active surveillance (AS) biopsies.
The study involved men who received MRI scans and 30 different biomarkers, analyzing their potential to predict reclassification on subsequent biopsies from January 2016 to June 2019.
RSI-MRI outperformed other non-imaging biomarkers, showing the highest prediction accuracy (AUC = 0.84), indicating its potential to enhance decision-making in AS protocols.